RU2017134857A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017134857A3 RU2017134857A3 RU2017134857A RU2017134857A RU2017134857A3 RU 2017134857 A3 RU2017134857 A3 RU 2017134857A3 RU 2017134857 A RU2017134857 A RU 2017134857A RU 2017134857 A RU2017134857 A RU 2017134857A RU 2017134857 A3 RU2017134857 A3 RU 2017134857A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15157742 | 2015-03-05 | ||
| EP15157742.6 | 2015-03-05 | ||
| EP15158781.3 | 2015-03-12 | ||
| EP15158781 | 2015-03-12 | ||
| EP15186626.6 | 2015-09-24 | ||
| EP15186626 | 2015-09-24 | ||
| PCT/EP2016/054524 WO2016139297A1 (en) | 2015-03-05 | 2016-03-03 | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021126914A Division RU2810206C1 (ru) | 2015-03-05 | 2016-03-03 | Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017134857A RU2017134857A (ru) | 2019-04-09 |
| RU2017134857A3 true RU2017134857A3 (enExample) | 2019-12-23 |
| RU2755691C2 RU2755691C2 (ru) | 2021-09-20 |
Family
ID=55453181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017134857A RU2755691C2 (ru) | 2015-03-05 | 2016-03-03 | Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10882905B2 (enExample) |
| EP (1) | EP3265807A1 (enExample) |
| JP (2) | JP7274259B2 (enExample) |
| KR (1) | KR102511343B1 (enExample) |
| CN (1) | CN107660150B (enExample) |
| AU (1) | AU2016227644B2 (enExample) |
| CA (1) | CA2972689A1 (enExample) |
| CL (1) | CL2017002237A1 (enExample) |
| CO (1) | CO2017008940A2 (enExample) |
| IL (1) | IL253292B2 (enExample) |
| MX (1) | MX2017010919A (enExample) |
| MY (1) | MY194040A (enExample) |
| PH (1) | PH12017501402A1 (enExample) |
| RU (1) | RU2755691C2 (enExample) |
| SG (1) | SG11201706879UA (enExample) |
| UA (1) | UA128752C2 (enExample) |
| WO (1) | WO2016139297A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102321172B1 (ko) * | 2013-09-05 | 2021-11-05 | 에이비2 바이오 에스에이 | 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) |
| MX2017010919A (es) | 2015-03-05 | 2017-12-07 | Ab2 Bio Sa | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. |
| WO2018119425A2 (en) * | 2016-12-22 | 2018-06-28 | Icahn School Of Medicine At Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
| KR20200066623A (ko) | 2017-09-06 | 2020-06-10 | 예일 유니버시티 | 인터류킨-18 변이체 및 사용 방법 |
| CN112105640B (zh) * | 2018-03-05 | 2025-03-04 | 詹森药业有限公司 | 检测神经退行性变的测定 |
| WO2020018364A1 (en) * | 2018-07-16 | 2020-01-23 | University Of Hawaii | Anti-galectin-9 antibody and methods of use thereof |
| CN108929382B (zh) * | 2018-07-20 | 2019-10-15 | 深圳市第三人民医院 | 一种抗serinc5的抗体及其应用 |
| EP3892300A4 (en) | 2018-12-03 | 2022-12-14 | Mabprotein Co.,Ltd. | ANTIBODIES RECOGNIZING A NEO-EPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND ASSOCIATED APPLICATION |
| MX2021008507A (es) | 2019-01-18 | 2021-09-21 | Univ Health Network | Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas. |
| US20220296707A1 (en) * | 2019-06-04 | 2022-09-22 | Regents Of The University Of Minnesota | Anti-opioid compounds and methods of making and using same |
| CN112582058B (zh) * | 2019-11-07 | 2022-04-01 | 广州医科大学 | 一种基于空气质量的慢阻肺发病预测方法及系统 |
| EP4146174A1 (en) | 2020-05-06 | 2023-03-15 | AB2 Bio SA | Il-18 binding protein (il-18bp) in respiratory diseases |
| GB202007404D0 (en) | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
| AU2021283858A1 (en) * | 2020-06-01 | 2023-01-05 | Avalo Therapeutics, Inc. | Methods and treatment involving antibodies to IL-18 |
| EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
| TW202233237A (zh) | 2020-11-18 | 2022-09-01 | 瑞士商諾華公司 | 用於在治療ｎｌｒｃ４－ｇｏｆ炎性體病變中使用的雙特異性抗體 |
| WO2023067348A1 (en) | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
| MX2024007616A (es) * | 2021-12-20 | 2024-09-04 | Avalo Therapeutics Inc | Métodos y tratamiento para la enfermedad de still de inicio en la edad adulta y la artritis idiopática juvenil de inicio sistemico que implica anticuerpos contra il-18. |
| CN117279950B (zh) * | 2022-01-28 | 2025-08-08 | 和径医药科技（上海）有限公司 | 一种靶向il-18bp的抗体及其应用 |
| EP4486367A1 (en) | 2022-03-04 | 2025-01-08 | AB2 Bio SA | Il-18 binding protein (il-18bp) in the treatment of vexas |
| MX2024011278A (es) * | 2022-03-15 | 2024-09-25 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer. |
| CN120693345A (zh) | 2023-01-06 | 2025-09-23 | 艾利妥 | 抗il18结合蛋白抗体及其使用方法 |
| IL321948A (en) | 2023-01-06 | 2025-09-01 | Lassen Therapeutics Inc | Anti-IL-18 BP antibodies |
| CN119192356B (zh) * | 2024-09-29 | 2025-05-27 | 华中农业大学 | 识别犬瘟热病毒h蛋白的单克隆抗体、检测试纸条及应用 |
| CN119241693B (zh) * | 2024-09-29 | 2025-05-27 | 华中农业大学 | 一种抗犬瘟热病毒的基因工程嵌合抗体及应用 |
| CN120349409A (zh) * | 2025-04-08 | 2025-07-22 | 生物岛实验室 | Il-18bp纳米抗体及其制备方法与应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| AU1235692A (en) | 1991-01-18 | 1992-08-27 | Synergen, Inc. | Methods for treating tumor necrosis factor mediated diseases |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| ES2176342T5 (es) | 1994-10-21 | 2010-02-09 | Innogenetics N.V. | Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos. |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| EP1110969A4 (en) * | 1998-09-01 | 2002-01-09 | Hayashibara Biochem Lab | INTERLEUKIN 18-BINDING PROTEINS |
| AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| JP2004500086A (ja) | 2000-02-10 | 2004-01-08 | アボット・ラボラトリーズ | ヒトインターロイキン１８に結合する抗体とその調整方法および使用方法 |
| UA94022C2 (ru) * | 2000-02-21 | 2011-04-11 | Апплайд Резеч Системз Арс Холдинг Н.В. | Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита |
| TR200202030T2 (tr) | 2000-02-21 | 2003-01-21 | Applied Research Systems Ars Holding N.V. | IL-18 inhibitörlerinin kullanımı. |
| SK287761B6 (en) | 2000-05-05 | 2011-09-05 | Applied Research Systems Ars Holding N. V. | Use of IL-18 inhibitor, use of an expressing vector which contains a sequence encoding IL-18 inhibitor, use of the vector for induction and/or amplifying endogenic production of IL-18 inhibitor in a cell and use a cell with production of IL-18 inhibitor |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
| WO2002032374A2 (en) * | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| DK1355668T3 (da) * | 2001-01-29 | 2008-05-05 | Serono Lab | Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom |
| JP4502580B2 (ja) | 2001-05-16 | 2010-07-14 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 敗血症の治療または予防のためのｉｌ−１８阻害剤の使用 |
| IL159014A0 (en) * | 2001-05-25 | 2004-05-12 | Ares Trading Sa | Use of il-18 inhibitors for treating or preventing cns injuries |
| MXPA04009135A (es) * | 2002-03-22 | 2004-12-07 | Applied Research Systems | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas. |
| WO2004032837A2 (en) * | 2002-10-08 | 2004-04-22 | Ares Trading S.A. | The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| ES2309508T3 (es) | 2003-03-11 | 2008-12-16 | Laboratoires Serono Sa | Vectores de expresion que comprenden el promotor de mcmv-ie2. |
| ATE549353T1 (de) | 2003-05-13 | 2012-03-15 | Merck Serono Sa | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| AU2011224023C1 (en) | 2003-11-12 | 2013-08-29 | Abbvie Inc. | IL-18 binding proteins |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| IL159670A0 (en) * | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
| WO2005087249A1 (ja) * | 2004-03-11 | 2005-09-22 | Kurume University | プロテアーゼ阻害剤及び疾患の予防又は治療剤 |
| US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| CN101039696B (zh) | 2004-08-20 | 2011-08-17 | 史密丝克莱恩比彻姆公司 | 给药人il-18治疗创伤的方法 |
| ES2370417T3 (es) | 2005-06-03 | 2011-12-15 | Ares Trading S.A. | Producción de una proteína de unión a il-18 recombinante. |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ATE503846T1 (de) | 2005-09-15 | 2011-04-15 | Val Chum S E C | Verfahren zur diagnose eines ovarialkarzinoms |
| WO2008091592A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| AU2011347354A1 (en) * | 2010-12-20 | 2013-08-01 | Medimmune Limited | Anti-IL-18 antibodies and their uses |
| JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| KR102321172B1 (ko) * | 2013-09-05 | 2021-11-05 | 에이비2 바이오 에스에이 | 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) |
| MX2017010919A (es) * | 2015-03-05 | 2017-12-07 | Ab2 Bio Sa | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. |
-
2016
- 2016-03-03 MX MX2017010919A patent/MX2017010919A/es unknown
- 2016-03-03 US US15/555,446 patent/US10882905B2/en active Active
- 2016-03-03 MY MYPI2017001041A patent/MY194040A/en unknown
- 2016-03-03 CN CN201680013699.2A patent/CN107660150B/zh active Active
- 2016-03-03 AU AU2016227644A patent/AU2016227644B2/en active Active
- 2016-03-03 JP JP2017546603A patent/JP7274259B2/ja active Active
- 2016-03-03 UA UAA201709701A patent/UA128752C2/uk unknown
- 2016-03-03 RU RU2017134857A patent/RU2755691C2/ru active
- 2016-03-03 CA CA2972689A patent/CA2972689A1/en active Pending
- 2016-03-03 KR KR1020177024957A patent/KR102511343B1/ko active Active
- 2016-03-03 EP EP16707773.4A patent/EP3265807A1/en active Pending
- 2016-03-03 WO PCT/EP2016/054524 patent/WO2016139297A1/en not_active Ceased
- 2016-03-03 SG SG11201706879UA patent/SG11201706879UA/en unknown
-
2017
- 2017-07-03 IL IL253292A patent/IL253292B2/en unknown
- 2017-08-04 PH PH12017501402A patent/PH12017501402A1/en unknown
- 2017-08-31 CO CONC2017/0008940A patent/CO2017008940A2/es unknown
- 2017-09-04 CL CL2017002237A patent/CL2017002237A1/es unknown
-
2020
- 2020-05-26 US US16/883,906 patent/US11820817B2/en active Active
-
2021
- 2021-03-08 US US17/195,518 patent/US11926663B2/en active Active
- 2021-07-07 JP JP2021112865A patent/JP2021176860A/ja active Pending
-
2024
- 2024-02-08 US US18/436,802 patent/US20240190952A1/en active Pending